Methods of treatment using proANF peptides
OwnerDavid L. Veselyinventor
Life of this patent
Estimating the term…
Abstract
A method of treatment of hypertension, congestive heart failure, pulmonary edema, nephrotic syndrome, acute and chronic renal failure, toxemia of pregnancy, hepatic cirrhosis, and/or hyperkalemia. Humans or other mammals are administered an effective amount of peptide(s) consisting of amino acids 1-30 (proANF 1-30), amino acids 31-67 (proANF 31-67) and amino acids 79-98 (i.e., proANF 79-98) of the human sequence of the atrial natriuretic factor (ANF) prohormone. Pharmaceutical compositions include such peptides in an effective concentration within a pharmaceutically acceptable liquid or solid carrier.
Claims25
A method of treating high blood pressure, congestive heart failure, pulmonary edema, toxemia of pregnancy, nephrotic syndrome, acute and chronic renal failure, hepatic cirrhosis with and without ascites;
- which method comprises administering to a mammal, including humans, a therapeutically effective amount of at least 95% pure synthetic peptide from the group of peptides consisting of amino acids 1-30 (i.e., proANF 1-30), amino acids 31-67 (i.e., proANF 31-67), and amino acids 79-98 (i.e., proANF 79-98) of the human sequence of the 126 amino acid atrial natriuretic factor prohormone;
- which have blood pressure lowering, water, sodium and/or potassium excreting properties in humans;
- and combinations thereof or a non-toxic salt thereof.
A pharmaceutical composition for treating high blood pressure, congestive heart failure, nephrotic syndrome, acute and chronic renal failure, toxemia of pregnancy, pulmonary edema, and hepatic cirrhosis, which composition consists essentially of a therapeutically effective amount of at least 98% pure synthetic human peptide which is selected from the group of proANF 1-30, proANF 31-67, proANF 79-98 and a combination thereof or non toxic salts thereof, plus a pharmaceutically acceptable liquid or solid carrier.
A method of treating sodium and water retaining conditions which include congestive heart failure, renal failure, toxemia of pregnancy, and hepatic cirrhosis with ascites comprising administering to a human a therapeutically effective amount of a 100% pure synthetic peptide from the group consisting of the human sequences proANF 1-30, proANF 31-67, proANF 79-98 and combinations thereof or a non-toxic salt thereof.
A method of regulating hypertension comprising administering to a human a therapeutically effective amount of at least 95% pure, synthetic peptide form the group of peptides consisting of the human sequenced proANF 1-30, proANF 31-67, proANF 79-98 and a combination thereof or a non-toxic salt thereof.
A method of treating hyperkalemia (i.e., high blood potassium) associated with acidosis, digitalis overdosage, succinylcholine, insulin deficiency, acute and chronic renal failure, Addison's disease (i.e., adrenal insufficiency) and the hypoaldosteronism comprised of administering to humans and other mammals a therapeutically effective amount of proANF 79-98 or proANF 1-30 or a combination thereof or non-toxic salt thereof.
Dependencies are inferred from the claim text.